carmustine / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 245 Diseases   54 Trials   54 Trials   1419 News 


«12...345678910111213...2021»
  • ||||||||||  carmustine / Generic mfg.
    Journal:  Potential Use of Nitrogen-Doped Carbon Nanotube Sponges as Payload Carriers Against Malignant Glioma. (Pubmed Central) -  Jun 3, 2021   
    The N-CNSs loaded with carmustine exhibited a continuous kinetic release of carmustine with a maximum release after 72 h. The cytotoxic effect of N-CNSs loaded with carmustine was similar to that of carmustine alone. The results demonstrated that N-CNSs are a biocompatible nanostructure that could be used as carriers for the tumoral load of large amounts of chemotherapeutic agents.
  • ||||||||||  temozolomide / Generic mfg.
    Clinical, Retrospective data, Journal:  Long-term follow-up after BCNU wafer implantation in patients with newly diagnosed glioblastoma. (Pubmed Central) -  Jun 1, 2021   
    1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU, or Carmustine) wafers are intraoperatively implantable wafers used to achieve local tumor control...We reviewed the data of 64 patients with newly diagnosed glioblastoma treated by surgery, BCNU wafers, radiation therapy, and temozolomide administration...Of note, 13 patients with first distant recurrence had no obvious radiological local tumor progression even at the terminal stage. Long-term follow-up after BCNU wafer implantation revealed that patients with first distant recurrence had long-lasting local tumor control until the terminal stage.
  • ||||||||||  temozolomide / Generic mfg.
    Review, Journal:  Biocompatible Copolymer Formulations to Treat Glioblastoma Multiforme. (Pubmed Central) -  May 15, 2021   
    The placement of carmustine wafers in the brain after tumour removal is added in cases of recurrent glioma...Firstly, we describe three common types of thermo-responsive polymers addressing the advantages and drawbacks of their formulations. Then, we focus on formulations specifically developed for GBM treatment.
  • ||||||||||  Zarzio (filgrastim biosimilar) / Novartis
    [VIRTUAL] INCIDENCE OF EARLY TOXICITIES AND MORTALITY AFTER 4 TYPES OF CONDITIONING REGIMENS FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH LYMPHOMAS: A RETROSPECTIVE ANALYSIS. () -  May 13, 2021 - Abstract #EHA2021EHA_747;    
    Until recently, carmustine, etoposide, cytarabine and melphalan (BEAM) was the most used conditioning regimen in this setting, given its acceptable efficacy and tolerability...Aims To compare toxicities of BEAM (Carmustine, Etoposide, Citarabina, Melphalan), CBV (Carmustine, Etoposide, Cyclophosphamide), BendaEAM (Bendamustine, Etoposide, Citarabina, Melphalan) and BuMel (Busulfan, Melphalan) conditioning regimens used for ASCT in patients with relapsed/refractory non-Hodgkin (NHL) and Hodgkin lymphomas(HL)...Conclusion BuMel and BendaEAM were associated with higher rate of grade III and IV toxicity however type of conditioning regimen was not ass associated with early mortality Carmustine based conditioning regimens appear to be less toxic and safer. BendaEAM was associated with an increased risk for death at 1 year after autologous transplantation for LNH and LH, but probably related to relapse Longer follow-up is needed to draw definitive conclusions on the use of BendaEAM to control lymphoma relapse.
  • ||||||||||  Zyclara (imiquimod) / Mochida, Mylan, Bausch Health
    [VIRTUAL] Dermatologists Are More Likely Than Oncologists to Prescribe Skin Directed Therapies for Early Stage () -  May 4, 2021 - Abstract #SID2021SID_865;    
    Our data showed that there was a statistically detectable relationship between the presence or absence of oncologist involvement and whether a patient would be prescribed skin directed therapy (p = 0.0003; Fisher’s Exact Test). Limitations identified in our study included the retrospective design, small sample size, and being a single academic center.
  • ||||||||||  melphalan / Generic mfg., mitoxantrone / Generic mfg.
    Clinical, Journal:  Comparison of mitoxantrone-melphalan and BEAM conditioning regimens in patients with lymphoma. (Pubmed Central) -  May 4, 2021   
    Although time to neutrophil engraftment was shorter in the BEAM arm, it did not result as significant transplant-related complications between the two regimens. The Mx-Mel regimen is seen as a good alternative with low toxicity and high efficacy.
  • ||||||||||  carmustine / Generic mfg.
    Journal:  Improved Synthesis of Phosphoramidite-Protected N-Methyladenosine via BOP-Mediated SAr Reaction. (Pubmed Central) -  Apr 14, 2021   
    We report an improved five-step synthesis of the mA phosphoramidite starting from inosine, utilising a 1-H-benzotriazol-1-yloxytris(dimethylamino)phosphoniumhexafluorophosphate (BOP)mediated SAr reaction in the key step. The route manifests a substantial increase in overall yield compared to reported routes, and is useful for the synthesis of phosphoramidites of other adenosine derivatives, such as ethanoadenosine, an RNA analogue of the DNA adduct formed by the important anticancer drug Carmustine.
  • ||||||||||  Avastin (bevacizumab) / Roche
    FDA event, Review, Journal:  Current FDA-Approved Therapies for High-Grade Malignant Gliomas. (Pubmed Central) -  Apr 7, 2021   
    The standard of care (SOC) for high-grade gliomas (HGG) is maximally safe surgical resection, followed by concurrent radiation therapy (RT) and temozolomide (TMZ) for 6 weeks, then adjuvant TMZ for 6 months...Outside of TMZ, there are four drugs and one device FDA-approved for the treatment of HGGs: lomustine, intravenous carmustine, carmustine wafer implants, bevacizumab (BVZ), and tumor treatment fields (TTFields)...TTFields is the only treatment that has been shown to improve OS (20.5 vs. 15.6 months) and PFS6 (56% vs. 37%) in comparison to the current SOC. TTFields is the newest addition to this list of FDA-approved treatments, but has not been universally accepted yet as part of SOC.
  • ||||||||||  Starasid (cytarabine ocfosfate) / Nippon Kayaku
    Trial completion date, Trial primary completion date, Gene therapy:  Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant (clinicaltrials.gov) -  Mar 12, 2021   
    P1/2,  N=18, Recruiting, 
    hdICE conditioning regimen may be used as an alternative to BEAM, with similar survival outcomes and toxicity profile, especially transplant centers that experience some difficulties in the availability of the carmustine. Trial completion date: Jun 2036 --> Sep 2024 | Trial primary completion date: Sep 2021 --> Sep 2022
  • ||||||||||  lomustine / Generic mfg., temozolomide / Generic mfg., carmustine / Generic mfg.
    Preclinical, Journal:  Design, synthesis, DNA binding studies and evaluation of anticancer potential of novel substituted biscarbazole derivatives against human glioma U87 MG cell line. (Pubmed Central) -  Mar 9, 2021   
    The compound 34 showed the most significant in vitro cytotoxicity (IC = 3.9 µM) against human glioma U87 MG cell line and was found to be better than standard drugs used for the treatment of brain tumors such as temozolomide (IC = 100 µM) and carmustine (IC = 18.2 µM) respectively...Our results demonstrated groove binding mode of interaction of the compound 34 with CT-DNA with a plausible static bio-molecular quenching rate constant (Kq) 1.7 × 10 M s. The studies of biscarbazole derivatives are anticipated to develop potential novel anticancer agents against brain tumors.
  • ||||||||||  bendamustine / Generic mfg.
    Trial completion, Trial completion date:  Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma (clinicaltrials.gov) -  Feb 21, 2021   
    P1/2,  N=34, Completed, 
    In conclusion, in this phase II study we found no indication of a positive effect of bortezomib maintenance after ASCT. Active, not recruiting --> Completed | Trial completion date: Jun 2021 --> Jun 2020